# Product Data Sheet

## **MCE** MedChemExpress

## ProTx-III

| Cat. No.:            | HY-P5153   |  |
|----------------------|--|--|
| Molecular Formula:   | $C_{162}H_{246}N_{52}O_{43}S_{6}$  |  |
| Molecular Weight:    | 3802.4   |  |
| Sequence:            | Asp-Cys-Leu-Lys-Phe-Gly-Trp-Lys-Cys-Asn-Pro-Arg-Asn-Asp-Lys-Cys-Cys-Ser-Gly-Leu-<br>Lys-Cys-Gly-Ser-Asn-His-Asn-Trp-Cys-Lys-Leu-His-Ile-NH2 (Disulfide bonds: Cys2-Cys1<br>7, Cys9-Cys22, Cys16-Cys29) |  |
| Sequence Shortening: | DCLKFGWKCNPRNDKCCSGLKCGSNHNWCKLHI (Disulfide bonds: Cys2-Cys17, Cys9-Cys 22, Cys16-Cys29)  |  |
| Target:              | Sodium Channel   |  |
| Pathway:             | Membrane Transporter/Ion Channel   |  |
| Storage:             | Please store the product under the recommended conditions in the Certificate of Analysis.  |  |

### BIOLOGICAL ACTIVITY

| Description   | ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Na <sub>v</sub> 1.7, with an IC <sub>50</sub> of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia <sup>[1]</sup> . |   |  |
|---------------|---|---|--|
| IC₅₀ & Target | Na <sub>v</sub> 1.7<br>2.1 nM (IC <sub>50</sub> )   |   |  |
| In Vitro      | ProTx-III in native, recombinant and synthetic C-terminal acid and amide forms inhibit hNaV1.7 with IC <sub>50</sub> s of 2.1, 9.5, 11.5<br>and 2.5 nM, respectively <sup>[1]</sup> .<br>.ProTx-III inhibits hNav1.7 without significantly altering the voltage dependence of activation or inactivation <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.                                    |   |  |
| In Vivo       | ProTx-III (0.01-1 μM; intraplantar injection) can proves to be analgesic by reversing spontaneous pain induces in mice by intraplantar injection in OD1 in mouse model <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |   |  |
|               | Animal Model:   | OD1-induced mouse model of pain(300Nm; intraplantar injection) <sup>[1]</sup>   |  |
|               | Dosage:   | 100 nM, 300 nM, 1µM   |  |
|               | Administration:   | intraplantar injection  |  |
|               | Result:   | Showed at 1 $\mu$ M (40 pmoles in a 40 $\mu$ l injection) and 300 nM (12 pmoles in a 40 $\mu$ l injection) significantly reduced spontaneous pain behaviour in a concentration dependent manner and this reduction in pain behaviour persisted for 25 min after injection of the highest concentration. |  |

### REFERENCES

[1]. Cardoso FC, et al. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens. Mol Pharmacol. 2015 Aug;88(2):291-303.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA